Prevail Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Prevail Therapeutics (Nasdaq: PRVL) announced participation in upcoming virtual investor conferences, featuring CEO Asa Abeliovich. The events include the Guggenheim Healthcare Talks on November 16, 2020, the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020. Webcasts of the presentations will be accessible on their website. Prevail focuses on developing AAV-based gene therapies for neurodegenerative diseases, with key products in development for Parkinson’s disease and frontotemporal dementia.

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the following virtual investor conferences in November and December:

• Guggenheim Healthcare Talks Idea Forum 2^nd Annual Neuro/Immunology Day on Monday, November 16, 2020.
  
  
• Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 10:40-11:10 a.m. ET.
  
  
• Piper Sandler 32^nd Annual Virtual Health Care Conference on Tuesday, December 1, 2020.
  

Webcasts of the presentations will be available under "Events and Presentations" in the Investors and Media section of the Company's website at ir.prevailtherapeutics.com following the presentations.

About Prevail Therapeutics
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD); PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson’s with GBA and OrbiMed, and is headquartered in New York, NY.

Media Contact:
Lisa Qu
Ten Bridge Communications
LQu@tenbridgecommunications.com
678-662-9166

Investor Contact:
investors@prevailtherapeutics.com

FAQ

What investor conferences will Prevail Therapeutics participate in November 2020?

Prevail Therapeutics will participate in the Guggenheim Healthcare Talks on November 16, 2020, and the Stifel 2020 Virtual Healthcare Conference on November 18, 2020.

When is the Piper Sandler Virtual Healthcare Conference for Prevail Therapeutics?

The Piper Sandler 32nd Annual Virtual Healthcare Conference will be held on December 1, 2020.

Where can I find webcasts of Prevail Therapeutics’ presentations?

Webcasts of Prevail Therapeutics’ presentations will be available on their website under 'Events and Presentations' following the events.

What is Prevail Therapeutics developing therapies for?

Prevail Therapeutics is developing AAV-based gene therapies for neurodegenerative diseases, focusing on Parkinson’s disease and frontotemporal dementia.